We're off to the races!

Update on uniQure's Hemophilia B Gene Therapy Program

The following is an excerpt from a press release from uniQure. Read the press release in its entirety here. uniQure announces the initial topline data from our Phase 2B dose-confirmation study of AMT-061, an investigational gene therapy for the treatment of patients with severe and moderately severe hemophilia B. All patients achieved and sustained therapeutic […]

Genentech to Present New Data at the American Society of Hematology 2018 Annual Meeting

 The following is an excerpt from a press release from Genentech. Read the press release in its entirety here. Genentech has announced new data that will be presented at this year’s annual American Society of Hematology meeting held in San Diego from Dec. 1-4. Ten Genentech medicines will be featured in more than 70 abstracts, including 25 […]

FDA Approves Genentech's Hemlibra

The following is an excerpt from a press release from Genentech. Read the entire press release here. Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Hemlibra®(emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, […]

Genentech Announces the Launch of New Safety Website

Genentech has announced a new web portal for patients and caregivers intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA. Visit the safety website: http://www.emipatientinfo.com/.Earlier this year, Genentech launched a similar site specifically for health care providers.In announcing the launch, Genentech stated “This website is meant to serve as […]

Phase III Results for Genentech's Hemlibra Published in New England Journal of Medicine

The following is an excerpt from a press release from Genentech. Read the press release in its entirety here.  Genentech, a member of the Roche Group, announced that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA®Â prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or […]

en_USEnglish